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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A163CS 200 mg/mL at 24 hours signiﬁcantly increased ATP production com-
pared to basal condition (0,55 mM vs 0,65 mM). After TNFa stimulation,
ATP production fell to 0,40 mM; but also in this case, CSwas able to inhibit
TNFa effect increasing the ATP synthesis up to 0,62 mM. Furthermore, we
have evaluated the effect ofCS on NO and ROS production. CS was able to
reduce NO synthesis induced by IL1b, TNFa or LPS. The NO levels were
reduced after cytokine stimulation up to 21%, 32% and 31% respectively.
On the other hand, in presence of IL1b, ROS production and SOD2 activity
were increased. In this case, intracellular ROS production as well as SOD
activity decreased in CS treated chondrocytes at an average of 80%. The
decreasewasmoremarked (up to 62%)whenwe speciﬁcally analysed the
mitochondrial isoform of this important antioxidant enzyme (SOD2).
Conclusions: In summary, CS improves mitochondrial activity in
human OA chondrocytes by affecting several mitochondrial processes.
The mitochondrial membrane hyperpolarization and the increased ATP
production could correlate with a greater resistance of CS treated
chondrocytes to apoptosis.Moreover, the reduction of NO and ROS
levels, as well as the reduction in SOD2 activity, provide evidence of the
effect of CS on oxidative stress regulation.
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EFFECT ON THE CHONDROCYTE PHENOTYPE BY SPECIFICALLY
INHIBITING THE b-CATENIN DEPENDENT WNT SIGNALING USING
SMALL PEPTIDES
A. Held y, A. Glas z, T. Grossmann z, T. Pap y, J. Bertrand y. y Inst. of
Experimental Musculoskeletal Med., Munster, Germany; zChemical
Genomics Ctr. (CGC) of the Max Planck Society, Dortmund, Germany
Purpose: In osteoarthritis (OA), chondrocytes undergo hypertrophic
differentiation. In course of phenotypic change of chondrocytes, the
matrix is remodeled, including down-regulation of genes such as ACAN,
COL2A1 and MMP13. One of the signaling pathways involved in this
chondrocyte differentiation is the canonical b-catenin dependent WNT
signaling pathway. SAH-BCL9 (stabilized alpha-helix of Bcl9) and StAx-
35R (stapled axin b-catenin binding domains), two small peptides have
been developed to inhibit the oncogenic canonical- WNT signaling by
directly targeting b-catenin. We hypothesized that SAH-BCL9 and StAx-
35R may inhibit the dedifferentiation of chondrocytes towards hyper-
trophy and may reduce OA-like changes in the cartilage.
Methods: In vitro analyses were performed using primary chondrocytes
isolated from neonatal mice. The peptides SAH-BCL9 and StAx-35R were
synthesized and provided by the Grossmann Lab at the Chemical
Genomics Centre (CGC) of theMax Planck Society in Dortmund, Germany.
Micromass cultures were stained with alcian blue to examine the pro-
teoglycanproduction. Expressionofmarkergenes (ACAN,COL2A1,MMP13
and AXIN2)wasmeasured by quantitative RT-PCR. Effects of the inhibitors
on the phosphorylation of LRP6 and on total b-catenin were analyzed
using Western Blot. With dual luciferase assays the efﬁcacy of the inhib-
itors on the TCF/LEF blockade was tested. Intracellular localization of the
inhibitors was investigated by using confocal laser microscopy.
Results: Based on ﬁrst results, confocal laser microscopy demonstrated
intracellular but not intranuclear localization of FITC-labeled SAH-BCL9
and StAx-35R peptides in primary chondrocytes and C28 cells, chon-
drocyte-like immortalized cells. Treatment of hip caps with inhibitors
showed better penetration into cartilage for SAH-BCL9, but not for StAx-
35R, independent of previous IL-1 treatment. TCF/LEF promotor activity
was reduced by application of increasing concentrations of SAH-BCL9,
but not with StAx-35R, upon simultaneous induction of the canonical
WNT signaling with WNT3A. Western blot analysis revealed that StAx-
35R did not affect pLRP6 and b-catenin. However ﬁrst results indicated
less phosphorylation of LRP6 and less stabilization of b-catenin when
cells were treated with SAH-BCL9 and WNT3A compared to cells which
were only treated with WNT3A alone. Quantitative RT-PCR showed
decreased expression of aggrecan, collagen type II and MMP13 upon
stimulation with WNT3A, which was not rescued to baseline by treat-
ment withWNT3A and either one of the inhibitors. Expression of Axin2,
a target gene of the canonical WNT signaling pathway, was increased by
WNT3A and still enhanced when cells were treated simultaneously
withWNT3A and SAH-BCL9 or StAx-35R.With regard to the phenotypic
stability of chondrocytes, alcian blue staining of micromass cultures
showed that WNT3A treatment led to proteoglycan loss, which could
not be reduced by using the small peptides.
Conclusions: Our data indicate that SAH-BCL9 inhibits the b-catenin
dependent WNT signaling pathway on protein level and functionally
with regard to the TCF/LEF reporter activity at high concentrations.Despite both - SAH-BCL9 and StAx-35R - appear to be not able to reverse
WNT3A induced changes on the chondrocyte phenotype.
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EFFECT OF GROWTH HORMONE AND HYALURONAN AMIDE
DERIVATIVE ON HUMAN OSTEOARTHRITIC CHONDROCYTES
F. Paolella y, E. Gabusi y, C. Manferdini y, L. Gambari y, A. Schiavinato z,
B. Grigolo y, G. Lisignoli y. y Istituto Ortopedico Rizzoli, Bologna, Italy;
z Fidia Farmaceutici s.p.a., Abano Terme, Padova, Italy
Purpose: Knee osteoarthritis (OA) is one of the main causes of pain and
disability and signiﬁcantly affects the patients’ quality of life. The
homeostasis of articular cartilage is mediated by a complex network of
interactions mainly due to locally produced growth factors, ECM com-
ponents and circulating hormones. The development of pharmaco-
logical treatments with the potential for structure-modifying activity in
OA joint treatment has become a major focus in the ﬁeld of OA research.
Aim of this study was to evaluate the effects of hyaluronan amide
derivative (HYADD®4-G, HAD) alone or in combination with human
growth hormone (hGH) on OA chondrocytes.
Methods: Chondrocytes were isolated from cartilage of OA patients
undergoing knee arthroplasty. Chondrocytes were treated with differ-
ent concentrations of hGH (from 0.01mg/ml to10mg/ml) with or without
HAD (1mg/ml) and analyzed at different time points (24, 48, 72 hours
and after 7 days). They were analyzed for: 1.the presence of GHR and
CD44 by immunocytochemistry, 2. cell viability by vital dye, 3. meta-
bolic activity by alamar blue assay, 4. the release of IGF-1, FGF2 and IL6
by immunoassay tests, 5. gene expression of collagen type 1, collagen
type 2, collagen type 10 and SOCS2 by qRT-PCR.
Results: OA chondrocytes express GH receptor and all doses of hGH
tested not affected cell viability and metabolic activity, as well as, the
expression of collagen type 2, 1, or 10 and the release of insulin like
growth factor-1 (IGF-1) or ﬁbroblast growth factor-2 (FGF-2) or IL6. hGH
treatment increased the expression of hyaluronan receptor CD44. HAD
alone or combined with hGH reduced metabolic activity, the release of
IL6 and the gene expression of collagen type 1, 2 and 10 , except SOCS2,
that was increased. Interestingly, all the parameters analyzed propor-
tionally decreased with increasing age of the patients.
Conclusions: hGH did not induce human chondrocyte metabolic
activity and did not affect typical chondrocytic (collagen type 2) or
ﬁbrotic or hypertrophic (collagen type 1 and 10) marker expression or
IGF1 or FGF2 or IL6 release but induced CD44 receptor. HAD reduced all
the effects induced by hGH on human OA chondrocytes partially
through a signiﬁcant induction of SOCS2 expression. It has been dem-
onstrated that SOCS2 is signiﬁcantly reduced in OA chondrocytes and
our preliminary results demonstrate an unknown interplays between
hGH and hyaluronic acid probably due to SOCS2.
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SANGUIS DRACONIS RESIN STIMULATES THE OSTEOGENESIS IN
OSTEOBLASTIC MC3T3-E1 CELLS IN VITRO
W. Wang y, P. Yuan z, X. Guo x. y The Second Afﬁliated Hosp., Xian Jiaotong
Uinversity, Xian, China; z Shaanxi Traditional Chinese Med. Coll., Xianyang,
China; xDept. of Publ. Hlth., Med. Coll., Key Lab. of Environment and Genes
Related to Diseases, Xian Jiaotong Uinversity, Xian, China
Purpose: Sanguis Draconis (SD)is a resin that is obtained from Dae-
monorops draco (Palmae). Used in traditional medicine, it has shown
activity in the prevention of osteoporosis as well as promoting the
healing of bone fractures.The purpose of this study was to investigate
the effect of SD on the MC3T3-E1 cells in vitro.
Methods: In this study, the effects of Sanguis Dranonis ethanol extract
on b-glycerolphosphate and ascorbic acid induced differentiation using
mouse calvaria origin MC3T3-E1 osteoblastic cells was examined. We
looked at osteoblast differentiation, proliferation, andmineralization by
measuring alkaline phosphatase (ALP) and speciﬁc bone marker activ-
ities. Osteoblast-like MC3T3-E1 cells were cultured in various concen-
trations of SD ethanol extract (0.005-1 mg/mL) during the osteoblast
differentiation period (1, 5, 15, and 25 days).
Results: As measured by 3-[4,5-dimethylthiazol-2-y]-2,5-diphenylte-
trazolium bromide assay, SD extracts increased cell proliferation as
compared to control. The most pronounced effect was observed at the
concentration range between 0.01 and 0.1 mg/mL (P<0.01). This SD
stimulatory effect for cell proliferation was observed during the whole
